会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • HETEROCYCLIC DERIVATIVE AND MEDICINE
    • 杂环衍生物和药物
    • WO1996007641A1
    • 1996-03-14
    • PCT/JP1995001792
    • 1995-09-08
    • NIPPON SHINYAKU CO., LTD.CHOKAI, ShoichiUKAI, YojiroAOKI, TomiyosiIDEGUCHI, Kyoichi
    • NIPPON SHINYAKU CO., LTD.
    • C07D213/64
    • C07D213/64C07D239/34C07D239/38C07D239/52C07D239/56C07D251/22C07D401/04C07D401/12C07D409/04
    • A medicine containing a compound represented by general formula (I) or a salt thereof as the active ingredient, having an excellent activity of inhibiting neuron necrosis, and being useful as a remedy for cerebrovascular disorder, wherein R represents aryl or heteroaryl; R represents hydrogen, alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, haloalkyl, alkoxy, alkylthio, amino, monoalkylamino, dialkylamino or phenyl; R and R represent each hydrogen or alkyl, or R and R are combined with the adjacent nitrogen atom to represent a 5- to 7-membered cyclic amino group NR R ; A represents C2-C10 alkylene; W represents O, S or (CH)n (wherein CH may be substituted by alkyl, and n represents 0, 1 or 2); and X, Y and Z represent each independently CH (wherein H may be replaced by alkyl) or N, provided the case where all of X, Y and Z are CH at the same time is excepted.
    • 含有由通式(I)表示的化合物或其盐作为活性成分的药物,具有优异的抑制神经元坏死的活性,可用作脑血管障碍的治疗剂,其中R 1表示芳基或杂芳基; R 2表示氢,烷基,烯基,环烷基,环烷基烷基,羟基烷基,卤代烷基,烷氧基,烷硫基,氨基,单烷基氨基,二烷基氨基或苯基; R 3和R 4各自代表氢或烷基,或R 3和R 4与相邻的氮原子结合,代表5-至7-元环氨基NR 3 R 4>; A表示C2-C10亚烷基; W表示O,S或(CH)n(其中CH可以被烷基取代,n表示0,1或2)。 X,Y和Z各自独立地表示CH(其中H可以被烷基取代)或N表示,只要X,Y和Z都同时为CH的情况除外。
    • 6. 发明申请
    • ASIALOTRISACCHARIDE MORANOLINE DERIVATIVES AND DRUGS
    • ASIALOTRISACCHARIDE MORANOLINE DORIVATIVES AND DRUGS
    • WO1997048712A1
    • 1997-12-24
    • PCT/JP1997002069
    • 1997-06-16
    • NIPPON SHINYAKU CO., LTD.OHGI, TadaakiISHIYAMA, KouichiMORI, Kazuya
    • NIPPON SHINYAKU CO., LTD.
    • C07H17/02
    • C07H17/02
    • Novel asialotrisaccharide moranoline derivatives represented by general formula (I) which inhibit selectins and thus are useful in the treatment of diseases such as inflammation wherein R represents (a) or (b); one of R and R represents galactopyranosyl optionally substituted at all or some of the hydroxyl groups by -SO3H, -CH2COOH or (c) while another represents fucopyranosyl; A represents -(CH2)m-NR -CO-O-, -CO-O-, -(CH2)n-CO-O-, -C2H4(OC2H4)z-NR -CO-O-, -C2H4(OC2H4)y-OCH2-CO-O- or -(CH2)n-O-; R and R are the same or different and each represents a saturated or unsaturated hydrocarbon group or a saturated or unsaturated fatty acid residue; R and R are the same or different and each represents hydroxy, alkyl or alkoxy; and R represents H or alkyl.
    • 抑制选择素的由通式(I)表示的新型脱二羟基山梨醇衍生物衍生物,因此可用于治疗诸如炎症的疾病,其中R代表(a)或(b); R 1和R 2中的一个表示通过-SO 3 H,-CH 2 COOH或(c)任选地在所有或一些羟基上被取代的吡喃半乳糖基,而另一个代表fucopyranosyl; A表示 - (CH 2)m -NR 6 -CO-O-,-CO-O-, - (CH 2)n -CO-O-,-C 2 H 4(OC 2 H 4)z -NR NR -CO-O - , - C 2 H 4(OC 2 H 4)y -OCH 2 -CO-O-或 - (CH 2)n O-; R a和R b相同或不同,各自表示饱和或不饱和烃基或饱和或不饱和脂肪酸残基; R c和R d相同或不同,各自表示羟基,烷基或烷氧基; R e表示H或烷基。
    • 7. 发明申请
    • ISCHEMIC HEART MUSCLE PROTECTIVE AGENTS
    • ISCHEMIC HEART MUSCLE保护剂
    • WO1997025987A1
    • 1997-07-24
    • PCT/JP1997000071
    • 1997-01-17
    • NIPPON SHINYAKU CO., LTD.FUJIWARA, HisayoshiYOSHIKUNI, YoshiakiOCHI, Seishi
    • NIPPON SHINYAKU CO., LTD.
    • A61K31/445
    • C07D471/04A61K31/437C07C215/42C07C2601/14C07D211/46
    • Ischemic heart muscle protecting agents and remedies for angina pectoris containing as the active ingredient compounds represented by general formula (I), wherein R , R and R are the same or different and each represents hydrogen, acyl, cyclohexanecarbonyl, alkoxyacetyl, naphthylcarbonyl, phenylalkanoyl, cinnamoyl, pyridinecarbonyl, dihydropyridinecarbonyl, thiophenecarbonyl, furylcarbonyl or benzyl; and A represents CH or N; provided that when A represents CH, then R represents hydroxy, R represents alkylamino and R represents hydroxymethyl or acyloxymethyl; while when A represents N, then R represents hydrogen, R represents hydroxymethyl or acyloxy, R represents alkyl, aryloxyalkyl or arylalkenyl, or R and R are combined together so that general formula (I) is represented by general formula (II).
    • 缺血性心肌保护剂和含有作为由通式(I)表示的活性成分化合物的心绞痛的治疗剂,其中R 1,R 2和R 3相同或不同,各自表示氢,酰基 环己烷羰基,烷氧基乙酰基,萘基羰基,苯基烷酰基,肉桂酰基,吡啶羰基,二氢吡啶羰基,噻吩羰基,呋喃基羰基或苄基; A表示CH或N; 条件是当A表示CH时,R 4表示羟基,R 5表示烷基氨基,R 6表示羟甲基或酰氧基甲基; 而当A表示N时,R 6表示氢,R 4表示羟甲基或酰氧基,R 5表示烷基,芳氧基烷基或芳基烯基,或R 4和R 5组合在一起, 式(I)由通式(II)表示。